scholarly journals Criteria for paediatric oral liquid form

2021 ◽  
Vol 5 (1) ◽  
pp. 018-019
Author(s):  
Gavrus Daniela ◽  
Busquets Ferran Bossacoma ◽  
Català Josep Maria ◽  
Genestar Joan Lluis Vinent ◽  
Flaque Miquel Villaronga
Keyword(s):  
Liquid Form ◽  
Oral Liquid

scholarly journals Oral liquid levothyroxine treatment at breakfast: a mistake?

2014 ◽  
Vol 170 (1) ◽  
pp. 95-99 ◽  
Author(s):  
Carlo Cappelli ◽  
Ilenia Pirola ◽  
Elena Gandossi ◽  
Annamaria Formenti ◽  
Maurizio Castellano
Keyword(s):  
Thyroid Hormone ◽  
Liquid Form ◽  
Coffee Intake ◽  
Tablet Form ◽  
Significant Difference ◽  
Oral Liquid ◽  
Euthyroid Patient ◽  
Tablet Formulations ◽  
Levothyroxine Treatment

ObjectiveTaking levothyroxine (l-T4) with coffee or with water followed by coffee intake within a few minutes results in poor TSH response in many patients. T4is available in tablet form worldwide, but novel formulations in soft gel capsule or liquid form are now available.DesignWe fortuitously identified a euthyroid patient who wrongly consumed liquidl-T4with coffee at breakfast; after changing the time of consumption to 30 min before breakfast, no change in TSH, free T4(fT4), and free tri-iodothyronine (fT3) concentrations was observed. Once the first patient was identified, additional stable euthyroid patients who consumed liquidl-T4with coffee were identified.MethodsPatients were recruited by searching our ‘thyroid patients’ database. All the patients on liquidl-T4treatment were contacted by phone to ask them whether they tookl-T4at breakfast. We identified 54 patients who were submitted to TSH, fT4, and fT3evaluation, with the indication that the same dosage ofl-T4be consumed 30 min before breakfast. We determined their TSH, fT4, and fT3concentrations after 3 and 6 months again.ResultsNo significant difference in thyroid hormone concentrations was observed in patients when they consumedl-T4at breakfast or when they consumed it 30 min before breakfast for 3 and 6 months (TSH: 2.5±1.1 vs 2.5±1.1 and 2.4±1.1 mIU/l respectively, fT4: 12.4±2.4 vs 12.5±2.4 and 12.3±2.1 pg/ml respectively, and fT3: 3.4±0.6 vs 3.4±0.6 and 3.3±0.5 pg/ml respectively).ConclusionOral liquidl-T4formulations could diminish the problem ofl-T4malabsorption caused by coffee when using traditional tablet formulations.

scholarly journals New liquid oral formulations of hydroxychloroquine: a physicochemical stability study

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Vincent Lebreton ◽  
Blandine Bourcier ◽  
Karine Cosson ◽  
Frédéric Lagarce ◽  
Laurence Spiesser-Robelet ◽  
...  
Keyword(s):  
Degradation Products ◽  
Storage Conditions ◽  
Stability Study ◽  
Physical Parameters ◽  
Suspension Stability ◽  
Liquid Form ◽  
Vehicle Suspensions ◽  
Stability Indicating Method ◽  
Oral Liquid ◽  
The Stability

Abstract Objectives Hydroxychloroquine (HCQ) presents many drug properties that increase its therapeutic use. There are, indeed, different research pathways in numerous autoimmune, inflammatory, and infectious diseases, as well as in cancerology. HCQ is only marketed as HCQ sulfate in film-coated or coated tablets for oral use. No pediatric liquid form is currently available on the market. The purpose of the present study is to develop oral liquid formulations for HCQ at 50 mg/mL with two different oral vehicle suspensions, namely ORA-Plus®/ORA-Sweet® (ORA) and Syrspend® SF PH 4 (SYR). Methods The suspension stability was assessed in different storage conditions (4 and 25 °C). A high-pressure liquid chromatography (HPLC) stability-indicating method with UV detection was developed to determine HCQ concentrations in the different formulations, and detect potential degradation products. Physical parameters, e.g. pH and osmolality were also monitored during the period of the stability study. Results HCQ concentration, osmolality, and pH remained stable for 90 days at 4 and 30 °C for HCQ in 50% ORA-Plus®/50% ORA-Sweet®. For HCQ suspension in SYR, the suspension remained stable 90 days at 4 °C and 60 days at 30 °C. Conclusions For all preparations, no significant physical or chemical modification was noticed during the period of the study.

Evaluation of Reproterol's Effectiveness in Preventing Exercise-Induced Bronchospasm in Children

1985 ◽  
Vol 13 (1) ◽  
pp. 19-23 ◽  
Author(s):  
M Verini ◽  
A Ansaloni ◽  
M G Di Vincenzo ◽  
M Napoleone ◽  
G Morgese
Keyword(s):  
Physical Exercise ◽  
Crossover Trial ◽  
Provocation Test ◽  
Italian Society ◽  
Liquid Form ◽  
Oral Liquid ◽  
Paediatric Age ◽  
Exercise Induced ◽  
Single Blind

The authors have evaluated the effectiveness of the protection of a new beta2-adrenergic compound, reproterol, against broncho-constriction induced by physical exercise in a group of individuals of paediatric age sensitive to broncho-stimulation. This study has been carried out comparing reproterol with salbutamol, using placebo as a control, following a randomized single-blind crossover trial. The provocation test has been performed following the instructions of the Italian Society of Paediatrics. The drugs have been administered in the oral liquid form at the dose of 0·28 mg/kg and 0·1 mg/kg of reproterol and salbutamol, respectively. The two substances have shown a similar preventive effectiveness in controlling exercise-induced asthma up to 2 hours from administration with reproterol having a stronger action at the beginning of the observation.

Oral liquid thyroxine assumed at breakfast: preliminary results of the TICO study

2015 ◽  
Author(s):  
Ilenia Pirola ◽  
Annamaria Formenti ◽  
Linda Daffini ◽  
Alessandra Cristiano ◽  
Elena Gandossi ◽  
...  
Keyword(s):  
Preliminary Results ◽  
Oral Liquid

Cytisine as an alternative smoking cessation product for Pacific smokers in New Zealand

2018 ◽  
Vol 21 (2) ◽  
pp. 89-95
Author(s):  
Vili Nosa ◽  
Kotalo Leau ◽  
Natalie Walker
Keyword(s):  
Smoking Cessation ◽  
New Zealand ◽  
Nicotinic Acetylcholine Receptors ◽  
Cultural Practices ◽  
Partial Agonist ◽  
Snowball Sampling ◽  
Structured Interviews ◽  
Liquid Form ◽  
Pacific People ◽  
The Pacific

ABSTRACT Introduction: Pacific people in New Zealand have one of the highest rates of smoking.  Cytisine is a plant-based alkaloid that has proven efficacy, effectiveness and safety compared to a placebo and nicotine replacement therapy (NRT) for smoking cessation.  Cytisine, like varenicline, is a partial agonist of nicotinic acetylcholine receptors, and blocks the rewarding effects of nicotine. Cytisine is naturally found in some plants in the Pacific region, and so may appeal to Pacific smokers wanting to quit. This paper investigates the acceptability of cytisine as a smoking cessation product for Pacific smokers in New Zealand, using a qualitative study design. Methods: In December 2015, advertisements and snowball sampling was used to recruit four Pacific smokers and three Pacific smoking cessation specialists in Auckland, New Zealand. Semi-structured interviews where undertaken, whereby participants were asked about motivations to quit and their views on smoking cessation products, including cytisine (which is currently unavailable in New Zealand). Interviews were recorded and transcribed verbatim, with thematic analysis conducted manually. Findings: Pacific smokers reported wanting to quit for loved ones and family, but did not find currently available smoking cessation products effective. Almost all participants had not previously heard of cytisine, but many of the Pacific smokers were keen to try it. Participants identified with cytisine on a cultural basis (given its natural status), but noted that their use would be determined by the efficacy of the medicine, its cost, side-effects, and accessibility. They were particularly interested in cytisine being made available in liquid form, which could be added to a “smoothie” or drunk as a “traditional tea”.  Participants thought cytisine should be promoted in a culturally-appropriate way, with packaging and advertising designed to appeal to Pacific smokers. Conclusions: Cytisine is more acceptable to Pacific smokers than other smoking cessation products, because of their cultural practices of traditional medicine and the natural product status of cytisine.

RANCANG BANGUN PERANGKAT EKSPERIMENTASI PROSES PIROLISIS BIOMASA GELOMBANG MIKRO

2013 ◽  
Vol 14 (2) ◽  
Author(s):  
Noor Fachrizal
Keyword(s):  
Large Scale ◽  
Continuous Model ◽  
Biomass Energy ◽  
Scale Model ◽  
Small Scale ◽  
Laboratory Apparatus ◽  
Liquid Form ◽  
Large Scale Model ◽  
Bio Oil ◽  
Pyrolysis Of Biomass

Biomass such as agriculture waste and urban waste are enormous potency as energy resources instead of enviromental problem. organic waste can be converted into energy in the form of liquid fuel, solid, and syngas by using of pyrolysis technique. Pyrolysis process can yield higher liquid form when the process can be drifted into fast and flash response. It can be solved by using microwave heating method. This research is started from developing an experimentation laboratory apparatus of microwave-assisted pyrolysis of biomass energy conversion system, and conducting preliminary experiments for gaining the proof that this method can be established for driving the process properly and safely. Modifying commercial oven into laboratory apparatus has been done, it works safely, and initial experiments have been carried out, process yields bio-oil and charcoal shortly, several parameters are achieved. Some further experiments are still needed for more detail parameters. Theresults may be used to design small-scale continuous model of productionsystem, which then can be developed into large-scale model that applicable for comercial use.

Development of Solid-Self Micron Emulsifying Drug Delivery Systems

2013 ◽  
Vol 6 (2) ◽  
pp. 2014-2021
Author(s):  
Preethi Sudheer ◽  
Koushik Y ◽  
Satish P ◽  
Uma Shankar M S ◽  
R S Thakur
Keyword(s):  
Drug Delivery ◽  
Systemic Circulation ◽  
Water Soluble ◽  
Future Research ◽  
Steady Increase ◽  
Liquid Form ◽  
Lipophilic Compounds ◽  
Modern Drug ◽  
Pharmaceutical Scientist ◽  
Pharmacologically Active

As a consequence of modern drug discovery techniques, there has been a steady increase in the number of new pharmacologically active lipophilic compounds that are poorly water soluble and solubility is one of the most important parameter to achieve desired concentration of drug in systemic circulation for therapeutic response. It is a great challenge for pharmaceutical scientist to convert those molecules into orally administered formulation with sufficient bioavailability.  Among the several approaches to improve oral bioavailability of these molecules, Self-micron emulsifying drug delivery system (SMEDDS) is one of the approaches usually used to improve the bioavailability of hydrophobic drugs. However, conventional SMEDDS are mostly prepared in a liquid form, which can have several disadvantages. Accordingly, solid SMEDDS (S-SMEDDS) prepared by solidification of liquid/semisolid self-micron emulsifying (SME) ingredients into powders have gained popularity. This article provides an overview of the recent advancements in S-SMEDDS such as methodology, techniques and future research directions.

Sign in / Sign up

Export Citation Format

Share Document